Alumis rises on licensing deal with Japan's Kaken
Source: SeekingAlpha
2025-03-25 06:53:09 ET
More on Alumis, Kaken Pharmaceutical Co., Ltd., etc.
- Acelyrin falls after reaffirming Alumis deal
- Alumis and Acelyrin to merge in all-stock deal
- Historical earnings data for Alumis
- Financial information for Alumis
- Historical earnings data for Kaken Pharmaceutical Co., Ltd.
Read the full article on Seeking Alpha
For further details see:
Alumis rises on licensing deal with Japan’s Kaken
Kaken Pharmaceutical Co Ltd
NASDAQ: KKPCF
KKPCF Trading
169.36% G/L:
$28.121 Last:
578 Volume:
$28.121 Open:
